Sarilumab
Sarilumab 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Polymyalgia Rheumatica。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
16 项
全球在招研究
5 项
已进入 III/IV 期
28 个
开展国家和地区
有
中国境内设点
药品与企业信息
研发企业
- Sanofi
- Regeneron Pharmaceuticals
- QuantumLeap Healthcare Collaborative
- University of Alabama at Birmingham
- NYU Langone Health
- University of Nebraska
- University of Southern California
- Duke University
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
美国、澳大利亚、比利时、法国、Israel、意大利、荷兰、South Korea、西班牙、英国、加拿大、中国台湾
正在招募患者的 Sarilumab 研究
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
I 期 / II 期招募中美国澳大利亚比利时法国NCT03564340I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
II 期招募中美国NCT01042379Phase 1b/2 Study of IV Sarilumab in Adult With RA
I 期 / II 期招募中美国NCT07704580RA-PRO PRAGMATIC TRIAL
III 期招募中美国加拿大NCT04692493Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
II 期招募中美国加拿大South Korea中国台湾NCT06787612Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma
II 期招募中美国NCT05428007A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
I 期 / II 期招募中美国比利时Brazil法国NCT04590326Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response
III 期招募中美国NCT03414502A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER)
I 期 / II 期招募中美国NCT04333706A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
II 期招募中美国NCT07154290Sarilumab Efficacy and Safety in Adults With Early Polymyalgia Rheumatica
III 期招募中美国奥地利比利时加拿大NCT07286214Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
不适用招募中美国加拿大NCT04278404A Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Systemic Juvenile Idiopathic Arthritis (SKYPS)
II 期招募中Argentina加拿大芬兰法国NCT02991469Clinical Trial Evaluating Methotrexate or Leflunomide + Targeted Therapy Versus Methotrexate or Leflunomide + Sulfasalazine + Hydroxychloroquine in Patients With Rheumatoid Arthritis and Insufficient Response to Methotrexate or Leflunomide
IV 期招募中法国NCT02714634Stand UP to Rheumatoid Arthritis (SUPRA)
不适用招募中加拿大NCT05305066Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
III 期招募中美国澳大利亚比利时加拿大NCT02735707
中国患者怎么争取用上这款药
这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。
查看完整申请指南本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。